Abstract
Clinical applications for positron emission tomography, PET, continue to increase particularly in the field of oncology. In parallel with this, large numbers of centers that are able to provide a clinical PET service have been opened in Japan. The first center of cancer screening using [18F] -fluorodeoxyglucose (FDG) -PET was started in 1994 and a high detection ratio of cancer screening with FDG-PET, compared with that of conventional cancer screening, is reported.
The new wave has already begun in the cancer screening. Will we ride the wave or simply be on-lookers?
